Grunnleggende statistikk
| CIK | 1353327 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Anbc, Inc.
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-51811 Shanghai Yutong Pharma, Inc Delaware 2023 11-36816111 (State or othe |
|
| April 17, 2007 |
EXHIBIT 16.1 Michael Pollack, Certified Public Accountant, Cherry Hill New Jersey March 22, 2007 Shanghai Yutong Pharma, Inc. Mr. Lu Jiang An No. 2020 Huqingping Rd. Qingpu District Shanghai, 201702 China Dear Mr Lu: Please accept this letter on behalf of Shanghai Yutong Pharma, Inc. as of written confirmation as to my resignation as the independent registered public accountant of record for the y |
|
| April 17, 2007 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report: April 12th, 2007 Date of Earliest Event Reported: March 22, 2007 Shanghai Yutong Pharma, Inc. |
|
| March 27, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-51811 (Check one) [X] Form 10-K and Form 10-KSB [ ] Form 11-K [ ] Form 20-F [ ] Form 10-Q and Form 10-QSB [ ] Form N-SAR For Period Ended: December 31, 2006 [ ] Transition Report on Form 10-K and Form 10-KSB [ ] Transition Report on Form 20-F [ ] Transition Re |
|
| November 14, 2006 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB (Mark One) xQUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30th, 2006 oTRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Shanghai Yutong Pharma, Inc. (Name of small business issuer in its charter) Delaware |
|
| September 18, 2006 |
Calculation of net profits explained Comment Number Page[s] Explanation 1 . 3 Calculation of net profits explained 2 . 10 Terms explained and disclosure expanded 3 . 7 Eliminated 4 . 15 Quantified 5 . 20 Revised to say 4 6 . Filed as Exhibit 12 7 . 30-31 Disclosure expanded 8 . As reflected in the restatement, the previous financial statements included a sale and a purchase, there was no offset. The Company has amended those financia |
|
| September 18, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 FORM 10 - SB GENERAL FORM FOR REGISTRATION OF SECURITIES OF SMALL BUSINESS ISSUERS Under Section 12(b) or (g) of the Securities Exchange Act of 1934 Shanghai Yutong Pharma, Inc. (Name of small business issuer in our charter) Delaware 2023 11-36816111 (State or other jurisdiction of incorporation or organization |
|
| September 18, 2006 |
February 1st, 2006 Shanghai Yutong, Pharma, Inc. Mr. Lu Jiang’an No. 2020 Huqingping Rd., Qingpu District, Shanghai, 201702 China Dear Mr Lu, We were previously the principal accountants for Shanghai Yutong Pharma, Inc. and we reported on the financial statements of Shanghai Yutong Pharma, Inc. as of the fiscal years ended December 31, 2005 and 2004. As of February 1, 2006, we were not engaged as |
|
| September 18, 2006 |
WILLIAMS LAW GROUP, P.A. 2503 W. Gardner Ct. Tampa FL 33611 Phone: 813-831-9348 Fax: 813-832-5284 e-mail: [email protected] September 18, 2006 Ms. Charito A. Mittelman United States Securities and Exchange Commission Division of Corporation Finance 100 F St., N.E. Washington, D.C. 20549-0408 Re: Shanghai Yutong Pharma, Inc. Registration Statement on Form 10-SB Amendment No. 2. File No. 0-5181 |
|
| August 21, 2006 |
BYLAWS SHANGHAI YUTONG PHARMA, INC. BYLAWS OF SHANGHAI YUTONG PHARMA, INC. Article 1. Offices The principal office of the corporation shall be located in Shanghai, China, or such other place as the Board of Directors may designate. The corporation may have such other offices, either within or without the state of its incorporation, as the Board of Directors may designate or as the business of the corporation may require from time to |
|
| August 21, 2006 |
WILLIAMS LAW GROUP, P.A. 2503 W. Gardner Ct. Tampa FL 33611 Phone: 813-831-9348 Fax: 813-832-5284 e-mail: [email protected] August 21, 2006 Ms. Charito A. Mittelman United States Securities and Exchange Commission Division of Corporation Finance 100 F St., N.E. Washington, D.C. 20549-0408 Re: Shanghai Yutong Pharma, Inc. Registration Statement on Form 10-SB Amendment No. 1. File No. 0-51811 D |
|
| August 21, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 FORM 10 - SB GENERAL FORM FOR REGISTRATION OF SECURITIES OF SMALL BUSINESS ISSUERS Under Section 12(b) or (g) of the Securities Exchange Act of 1934 Shanghai Yutong Pharma, Inc. (Name of small business issuer in our charter) Delaware 2023 11-36816111 (State or other jurisdiction of incorporation or organization |
|
| August 21, 2006 |
The meaning of this equity position has been clarified. Comment Number Page[s] Explanation 1 . 1 The meaning of this equity position has been clarified. 2 . 1 The discussion of this contract has been expanded. 3 . 5 The disclosure concerning this agreement has been revised and expanded and the agreement filed as an exhibit. 4 . 3 None. 5 . 4 Revised as only the Qilisheng product bears this trademark. 6 . 4 Licenses, permits, etc. are not required. Disc |
|
| August 21, 2006 |
Medicines Distributor of Beijing Contract EX-2 5 ex2.htm EX-2 Medicines Distributor of Beijing Contract Jia Side: Shanghai Yutong Pharmaceuticals Co, LTD Yi Side: Beijing Guo Xin Hua An Pharmaceutical Co. LTD Based on the mutually beneficially principle, both sides equally and voluntarily signed an agreement that Jia side trust Yi side with above products distributing in Beijing, detailed as below: 1. Product Name: Qi-Li-Sheng immunity Ba |
|
| July 13, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 - SB GENERAL FORM FOR REGISTRATION OF SECURITIES OF SMALL BUSINESS ISSUERS Under Section 12(b) or (g) of the Securities Exchange Act of 1934 Shanghai Yutong Pharma, Inc. (Name of small business issuer in our charter) Delaware 2023 11-36816111 (State or other jurisdiction of incorporation or organization) (Primary Stand |
|
| July 13, 2006 |
BYLAWS SHANGHAI YUTONG PHARMA, INC. BYLAWS OF SHANGHAI YUTONG PHARMA, INC. Article 1. Offices The principal office of the corporation shall be located in Shanghai, China, or such other place as the Board of Directors may designate. The corporation may have such other offices, either within or without the state of its incorporation, as the Board of Directors may designate or as the business of the corporation may require from time to |
|
| March 13, 2006 |
Shanghai Yutong Pharma, Inc. March 11, 2006 Mr. Thomas Flinn United States Securities and Exchange Commission Division of Corporation Finance 450 Fifth Street, N.W. Washington, D.C. 20549-0408 Re: Shanghai Yutong Pharma, Inc. Withdrawl File No. 0-51811 Dear Mr. Flinn: Please withdraw the above registration statement. The reason for the withdrawal is due to a change in accountants pursuant to issue |
|
| February 16, 2006 |
STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION CHILD VISION, INC. STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION CHILD VISION, INC. |
|
| February 16, 2006 |
AGREEMENT FOR THE PURCHASE OF COMMON STOCK AGREEMENT FOR THE PURCHASE OF COMMON STOCK THIS COMMON STOCK PURCHASE AGREEMENT, (the “AGREEMENT”) made this 3rd day of June, 2005, by and among Shanghai Yutong Pharmaceuticals, Inc. |
|
| February 16, 2006 |
CERTIFICATE OF INCORPORATION CHILD VISION, INC. CERTIFICATE OF INCORPORATION OF CHILD VISION, INC. FIRST: The name of the corporation is CHILD VISION, INC. SECOND: Its registered office in the State of Delaware is located at 2711 Centerville Road, Suite 400, in the city of Wilmington, County of New Castle, 19808. The registered agent in charge thereof is The Company Corporation. THIRD: The purpose of the corporation is to engage in any lawful a |
|
| February 16, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10 - SB GENERAL FORM FOR REGISTRATION OF SECURITIES OF SMALL BUSINESS ISSUERS Under Section 12(b) or (g) of the Securities Exchange Act of 1934 Shanghai Yutong Pharma, Inc. (Name of small business issuer in our charter) Delaware 2023 11-36816111 (State or other jurisdiction of incorporation or organization) (Primary Stand |
|
| February 16, 2006 |
Qi-li-sheng Immunity Oral Solution Cooperation and Execution Qi-li-sheng Immunity Oral Solution Cooperation and Execution Contract (Jia side) Beijing De-rui-tang Biology and Health Development Co. |
